Xinzhong Zhu1,2,3, Di Dong4,5, Zhendong Chen6,7, Mengjie Fang6,8, Liwen Zhang6, Jiangdian Song6, Dongdong Yu6,8, Yali Zang6,8, Zhenyu Liu6,8, Jingyun Shi9, Jie Tian10,6,8. 1. School of Life Science and Technology, XIDIAN University, Xi'an, Shanxi, China. zxz@zjnu.edu.cn. 2. CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. zxz@zjnu.edu.cn. 3. College of Mathematics, Physics and Information Engineering, Zhejiang Normal University, Jinhua, Zhengjiang, China. zxz@zjnu.edu.cn. 4. CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. di.dong@ia.ac.cn. 5. University of Chinese Academy of Sciences, Beijing, China. di.dong@ia.ac.cn. 6. CAS Key Lab of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China. 7. College of Mathematics, Physics and Information Engineering, Zhejiang Normal University, Jinhua, Zhengjiang, China. 8. University of Chinese Academy of Sciences, Beijing, China. 9. Department of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji, China. shijingyun89179@126.com. 10. School of Life Science and Technology, XIDIAN University, Xi'an, Shanxi, China.
Abstract
OBJECTIVES: To distinguish squamous cell carcinoma (SCC) from lung adenocarcinoma (ADC) based on a radiomic signature METHODS: This study involved 129 patients with non-small cell lung cancer (NSCLC) (81 in the training cohort and 48 in the independent validation cohort). Approximately 485 features were extracted from a manually outlined tumor region. The LASSO logistic regression model selected the key features of a radiomic signature. Receiver operating characteristic curve and area under the curve (AUC) were used to evaluate the performance of the radiomic signature in the training and validation cohorts. RESULTS: Five features were selected to construct the radiomic signature for histologic subtype classification. The performance of the radiomic signature to distinguish between lung ADC and SCC in both training and validation cohorts was good, with an AUC of 0.905 (95% confidence interval [CI]: 0.838 to 0.971), sensitivity of 0.830, and specificity of 0.929. In the validation cohort, the radiomic signature showed an AUC of 0.893 (95% CI: 0.789 to 0.996), sensitivity of 0.828, and specificity of 0.900. CONCLUSIONS: A unique radiomic signature was constructed for use as a diagnostic factor for discriminating lung ADC from SCC. Patients with NSCLC will benefit from the proposed radiomic signature. KEY POINTS: • Machine learning can be used for auxiliary distinguish in lung cancer. • Radiomic signature can discriminate lung ADC from SCC. • Radiomics can help to achieve precision medical treatment.
OBJECTIVES: To distinguish squamous cell carcinoma (SCC) from lung adenocarcinoma (ADC) based on a radiomic signature METHODS: This study involved 129 patients with non-small cell lung cancer (NSCLC) (81 in the training cohort and 48 in the independent validation cohort). Approximately 485 features were extracted from a manually outlined tumor region. The LASSO logistic regression model selected the key features of a radiomic signature. Receiver operating characteristic curve and area under the curve (AUC) were used to evaluate the performance of the radiomic signature in the training and validation cohorts. RESULTS: Five features were selected to construct the radiomic signature for histologic subtype classification. The performance of the radiomic signature to distinguish between lung ADC and SCC in both training and validation cohorts was good, with an AUC of 0.905 (95% confidence interval [CI]: 0.838 to 0.971), sensitivity of 0.830, and specificity of 0.929. In the validation cohort, the radiomic signature showed an AUC of 0.893 (95% CI: 0.789 to 0.996), sensitivity of 0.828, and specificity of 0.900. CONCLUSIONS: A unique radiomic signature was constructed for use as a diagnostic factor for discriminating lung ADC from SCC. Patients with NSCLC will benefit from the proposed radiomic signature. KEY POINTS: • Machine learning can be used for auxiliary distinguish in lung cancer. • Radiomic signature can discriminate lung ADC from SCC. • Radiomics can help to achieve precision medical treatment.
Authors: Balaji Ganeshan; Vicky Goh; Henry C Mandeville; Quan Sing Ng; Peter J Hoskin; Kenneth A Miles Journal: Radiology Date: 2012-11-20 Impact factor: 11.105
Authors: Viswam S Nair; Olivier Gevaert; Guido Davidzon; Sandy Napel; Edward E Graves; Chuong D Hoang; Joseph B Shrager; Andrew Quon; Daniel L Rubin; Sylvia K Plevritis Journal: Cancer Res Date: 2012-06-18 Impact factor: 12.701
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Haruka Itakura; Achal S Achrol; Lex A Mitchell; Joshua J Loya; Tiffany Liu; Erick M Westbroek; Abdullah H Feroze; Scott Rodriguez; Sebastian Echegaray; Tej D Azad; Kristen W Yeom; Sandy Napel; Daniel L Rubin; Steven D Chang; Griffith R Harsh; Olivier Gevaert Journal: Sci Transl Med Date: 2015-09-02 Impact factor: 17.956
Authors: Marc Oliver Bodendorf; Victor Haas; Hans-Gerd Laberke; Gunnar Blumenstock; Peter Wex; Thomas Graeter Journal: Lung Cancer Date: 2008-09-14 Impact factor: 5.705
Authors: Ji Eun Park; Donghyun Kim; Ho Sung Kim; Seo Young Park; Jung Youn Kim; Se Jin Cho; Jae Ho Shin; Jeong Hoon Kim Journal: Eur Radiol Date: 2019-07-26 Impact factor: 5.315